Appendix 3X (Initial Director’s Interest Notice) in relation to the appointment of Dr. Hazle effective July 30th, 2018.
View and download Appointment of Director and Appendix 3X.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)